USA, Peru, Brazil I 01-I-0079 Completed VRC4302 DNA USA I 04/ Completed APL
|
|
|
- Oliver Hood
- 5 years ago
- Views:
Transcription
1 Phase Trial D Status Prime Boost 1 Boost 2 Strategy Location HVTN 117 VA Ongoing Ad26.Mos.HV Ad26.Mos4.HV gp140 C Rwanda C89220HPX200 4 Trivalent Vector -, b HVTN 704 AMP Ongoing VRC-HVMAB AB Passive, Peru, Brazil Completed VRC / Completed APL GENEVAX-HV Ongoing Passive Germany, Completed gp160 Vaccine (mmuno-ag) Completed APL GENEVAX-HV / ACTG 326; PACTG 326 Completed ALVAC vcp1452 ADSVAX B/B Ad26.ENVA.01 Completed Ad26.EnvA-01 Ad26.ENVA.01 Ongoing Ad26.EnvA-01 Mucosal/PCAV D003 Ad5HVR48.EN Ongoing Ad5HVR48.EN VA.01 VA.01 ANRS VAC 01 Completed ALVAC vcp125 gp160 Vaccine France ANRS VAC 02 Completed rgp peptide V3 ANRS VAC 02 ANRS VAC 03 Completed ALVAC-HV (mmuno-ag) CLTB-36 (gp24e-v3 MN) France France
2 ANRS VAC 04 Completed LPO-6 France ANRS VAC 04 Completed LPO-6 France bis ANRS VAC 05 Completed ALVAC vcp125 ALVAC (vcp rage), Viral France ANRS VAC 06 Completed ALVAC vcp125 ALVAC (vcp rage), Viral ANRS VAC 07 Completed ALVAC vcp300 ANRS VAC 08 Completed ALVAC-HV ANRS VAC 09 Completed ALVAC-HV ALVAC vcp300 LPO-6, Viral, France France France France ANRS VAC 09 Completed LPO-6 France bis ANRS VAC 10 Completed ALVAC LPO-6T LPO-5 France vcp1452, ANRS VAC 12 Completed LPHV1 France ANRS VAC 14 Terminated gp160 MN/LA France ANRS VAC 16 Completed LPHV1 France ANRS VAC 17 Completed LPO-6 France ANRS VAC 18 Completed LPO-5 France APL RX101 Completed APL GENEVAX-HV AVEG 002 Completed HVAC-1e gp160 MN/LA AVEG 002A Completed HVAC-1e
3 AVEG 002B Completed HVAC-1e VaxSyn gp160 Vaccine (MicroGeneSys) AVEG 003 Completed VaxSyn gp160 Vaccine (MicroGeneSys) AVEG 003A Completed VaxSyn gp160 Vaccine (MicroGeneSys) AVEG 003B Completed VaxSyn gp160 Vaccine (MicroGeneSys) AVEG 004 Completed gp160 Vaccine (mmuno-ag) AVEG 004A Completed gp160 Vaccine (mmuno-ag) AVEG 004B Completed gp160 Vaccine (mmuno-ag) AVEG 005A/B Completed Env 2-3 AVEG 005C Completed Env 2-3 AVEG 006X; Completed MN rgp120 VEU 006 AVEG 007A/B Completed rgp120/hv-1 AVEG 007C Completed rgp120/hv-1 AVEG 008 Completed HVAC-1e AVEG 009 Completed MN rgp120 AVEG 010 Completed HVAC-1e rgp120/hv-1 MN rgp120, AVEG 011 Completed UB HV-1 Peptide
4 mmunogen, Multivalent AVEG 012A/B Completed ALVAC vcp125 AVEG 013A Completed gp160 Vaccine (mmuno-ag) AVEG 013B Completed gp160 Vaccine (mmuno-ag) AVEG 014A/B Completed TBC-3B AVEG 014C Completed TBC-3B MN rgp120 AVEG 015 Completed rgp120/hv-1 AVEG 016 Completed MN rgp120 AVEG 016A Completed MN rgp120 AVEG 016B Completed MN rgp120 AVEG 017 Completed UB HV-1 Peptide Vaccine, Microparticulate Monovalent AVEG 018 Completed UB HV-1 Peptide Vaccine, Microparticulate Monovalent AVEG 019 Completed p17/p24:ty- Virus Like VLP Particles AVEG 020 Completed gp120 C4-V3 AVEG 021 Completed P3C541b Lipopeptide AVEG 022 Completed ALVAC-HV
5 AVEG 022A Completed ALVAC-HV AVEG 023 Completed UB HV-1 Peptide mmunogen, Multivalent rgp120/hv-1 AVEG 024 Completed rgp120/hv-1 AVEG 026 Completed ALVAC vcp300 rgp120/hv-1 AVEG 027 Completed ALVAC-HV AVEG 028 Completed Salmonella typhi CVD 908-HV-1 LA gp 120 AVEG 029 Completed ALVAC-HV MN rgp120 rgp120/hv-1 AVEG 031 Completed APL ALVAC-HV AVEG 032 Completed ALVAC-HV AVEG 033 Completed ALVAC-HV AVEG 034/034A Completed ALVAC vcp1433 rgp120/hv-1 ALVAC vcp1452 ALVAC-HV Bacterium + gp 120,, Viral, Viral,
6 AVEG 036 Completed MN rgp120 ADSVAX B/E, AVEG 038 Completed ALVAC-HV AVEG 201 Completed rgp120/hv-1 AVEG Completed ALVAC-HV 202/HVNET 014 MN rgp120 rgp120/hv-1, / C Completed GTU-MultiHV Finland C86P1 Completed HV gp140 ZM96 United Kingdom Cervico-vaginal Completed CN54gp140 United Kingdom CN54gp140-hs p70 Conjugate Vaccine (TL01) CM235 and SF2gp120 CM235gp120 and SF2gp120 Completed Completed CM235 (ThaiE) gp120 plus SF2(B) gp120 CM235 (ThaiE) gp120 plus SF2(B) gp120 rgp120/hv-1 rgp120/hv-1, Thailand, Thailand CombiHVvac ( KombiVChvak) Scheduled CombiHVvac Virus Like Particles Russian Federation CRC282 Completed P2G12 Passive United Kingdom CRO2049/ CUT*HVAC001 Ongoing GTU-MultiHV United Kingdom CUTHVAC002 Ongoing -C CN54ENV CN54gp140, United Kingdom DCVax-001 Completed DCVax Completed -4 Russian
7 Federation DP6?001 Completed DP6?001 DP6 protein, DVP-1 Closed to follow-envdnup EnvPro PolyEnv1,, EN41-UGR7C Completed EN41-UGR7C United Kingdom Env Closed to follow-envdnup EnvPro Completed EnvPro EuroNeut41 Completed EN41-FPA2 United Kingdom EV01 Completed NYVAC-C Switzerland, United Kingdom / EV02 (EuroVacc 02) Completed -C NYVAC-C, Viral Switzerland, United Kingdom / EV03/ANRSVA Completed -C NYVAC-C, Viral France, C20 Germany, Switzerland, Extention HVTN 073E/SAAV 102 United Kingdom Completed Sub C gp140 / F4/AS01 Completed F4/AS01 Belgium FT Biotech Completed GTU-Nef Finland Guangxi CDC Completed Chinese China vaccine HGP-30 memory responses Completed HGP-30 HV-CORE002 Completed ChAdV63.HVc onsv MVA.HVconsv psg2.hvconsv, HV-POL-001 Completed MVA-mBN32 United Kingdom Germany
8 HVS 01 Completed HVS- Sweden HVS 02 Completed MVA-CMDR Sweden / HVS 03 Closed to follow-hvs-dnup MVA-CMDR, Viral Tanzania HVS 05 Completed HVS- MVA-CMDR, Viral Sweden / HVS06 Completed HVS- MVA-CMDR, Viral Tanzania HVS07 Completed HVS- MVA-CMDR, Viral Sweden HVNET 007 Completed ALVAC-HV Uganda HVNET 026 Completed ALVAC vcp1452 MN rgp120 Brazil, Haiti, Peru, Trinidad & Tobago HPTN 027 Completed ALVAC-HV Uganda vcp1521 HVRF Completed Vichrepol Russian Federation HVTN 039 Completed ALVAC vcp1452 HVTN 040 Completed AVX101 Alphavirus HVTN 041 Completed rgp120w61d / HVTN 042 / Completed ALVAC LPO-5 ANRS VAC 19 vcp1452 HVTN 044 Completed VRC-HV VP HVTN 045 Completed pga2/js7 HVTN 048 Completed EP HV-1090 Botswana, HVTN 049 Completed Gag and Env /PLG Oligomeric gp140/mf59,
9 HVTN 050/Merck 018 Terminated microparticles MRKAd5 HV-1 gag Brazil, Dominican Republic, Haiti, Malawi, Peru, Thailand, b HVTN 052 Completed VRC-HV VP HVTN 054 Completed VRC-HVADV VP HVTN 055 Completed TBC-M335 TBC-M358 TBC-F357 Brazil,, Viral, HVTN 056 Completed MEP HVTN 057 Completed VRC-HV0 VRC-HVADV0, Viral VP VP Vector - HVTN 059 Completed AVX101 Alphavirus Botswana, HVTN 060 Completed HV-1 gag Thailand, HVTN 063 Completed HV-1 gag HVTN 064 Completed EP HV-1043 EP HV-1090, HVTN 065 Completed pga2/js7 MVA/HV62, Viral HVTN 067 Completed EP-1233 MVA-mBN32, Viral a HVTN 068 Completed VRC-HVADV0 VRC-HVADV VP VP b HVTN 069 Completed VRC-HV VP VRC-HVADV VP Vector -, Viral Vector -
10 HVTN 070 Completed PENNVAX-B b HVTN 071 Terminated MRKAd5 HV-1 gag b HVTN 072 Completed VRC-HV0 VRC-HVADV0 VRC-HVADV0, Viral VP VP VP Vector -, HVTN 073 Completed SAAV -C2 SAAV MVA-C, Viral HVTN 076 Ongoing VRC-HV0 VRC-HVADV0, Viral VP b HVTN 077 Completed VRC-HVADV VP VP VRC-HVADV VP b HVTN 078 Completed NYVAC-B VRC-HVADV VP VRC-HV VP Vector - Vector -,, Viral Vector - HVTN 080 Completed PENNVAX-B b HVTN 082 Completed VRC-HV0 VRC-HVADV0, Viral VP VP Vector - HVTN 083 Ongoing VRC-HVADV0 VRC-HVADV0 VRC-HVADV VP VP VP HVTN 084 Ongoing VRC-HVADV VP b HVTN 085 Ongoing VRC-HVADV VP VRC-HVADV VP VRC-HVADV VP VRC-HVADV VP Vector -, Vector - Vector -, Switzerland Peru, Brazil,, Swaziland, Peru, Brazil, Switzerland
11 HVTN 086, SAAV 103 Ongoing SAAV MVA-C SAAV -C2 Oligomeric gp140/mf59 HVTN 087 Completed HV-MAG VSV-ndiana HV gag vaccine HVTN 088 Completed Oligomeric gp140/mf59 HVTN 090 Completed VSV-ndiana HV gag vaccine HVTN 092 Ongoing -HV- PT123 NYVAC-HV- PT1 NYVAC-HV- PT4,,, Viral Vector - Replicating Replicating, Viral, HVTN 094 Completed GEO-D03 MVA/HV62, Viral HVTN 096 Completed -HV- NYVAC-HV- NYVAC-HV- PT123 PT1 PT4, Viral, South Africa, Switzerland Switzerland HVTN 097 Ongoing ALVAC-HV ADSVAX B/E South Africa vcp1521 HVTN 098 Ongoing PENNVAX-GP / HVTN 100 Ongoing ALVAC-HV-C (vcp2438) Bivalent Subtype C South Africa HVTN 101 Scheduled -HV- PT123 HVTN 102 Withdrawn -HV- PT123 HVTN 104 Completed VRC-HVMAB AB gp120/mf59 NYVAC-HV- PT1 NYVAC-HV- PT1 ADSVAX B/E, ADSVAX B/E, Viral, Passive
12 b HVTN 105 Completed ADSVAX B/E -HV- PT123 HVTN 106 Ongoing Nat-B env Mosaic Env / HVTN 108 Ongoing -HV- PT123 Bivalent Subtype C gp120/as01b MVA-CMDR Bivalent Subtype C gp120/mf59,,,,, HVTN 110 Ongoing Ad4-mgag Ad4-EnvC150 ADSVAX B/E Replicating, Replicating, HVTN 111 Ongoing -HV- PT123 /MF59 vaccine, HVTN 112 Ongoing HV-1 nef/tat/vif, rvsv envc, Viral env p vaccine Vector - Replicating HVTN 114; Scheduled ADSVAX B/E MVA/HV62, Viral GOVX-B11 HVTN 116 Ongoing VRC-HVMAB0 VRCHVMAB08 Passive AB 0-00-AB, Passive HVTN 118 PCAVD-012 Ongoing Ad26.Mos4.HV gp140 C Mosaic gp140,, HVTN 203 Completed ALVAC vcp1452 ADSVAX B/B, HVTN 204 Closed to follow-vrc-hvup VRC-HVADV0, Viral VP VP Vector - a HVTN 205 Completed pga2/js7 MVA/HV62, Viral Zambia, Tanzania, South Africa, Kenya, Rwanda Peru,
13 b HVTN 502/Merck 023 (Step Study) Terminated MRKAd5 HV-1 gag/pol/nef b HVTN 503 (Phambili) Terminated MRKAd5 HV-1 gag/pol/nef b HVTN 505 Terminated VRC-HV0 VRC-HVADV VP VP HVTN 702 Ongoing ALVAC-HV-C Bivalent (vcp2438) Subtype C gp120/mf59 b HVTN 703 AMP Ongoing VRC-HVMAB AB, Viral Vector - Passive Australia, Canada, Dominican Republic, Haiti, Peru, Puerto Rico, South Africa South Africa Kenya, Malawi, Mozambique, Tanzania, Botswana Peru, HVTN 908 Completed pga2/js7 MVA/HV62, Viral AV 001 Completed.HVA United Kingdom AV 002 Completed.HVA Kenya AV 003 Completed MVA.HVA United Kingdom AV 004 Completed MVA.HVA Kenya AV 005 Completed.HVA MVA.HVA, Viral United Kingdom / AV 006 Completed.HVA MVA.HVA, Viral United Kingdom AV 008 Completed MVA.HVA Kenya AV 009 Completed.HVA MVA.HVA, Viral Uganda
14 a AV 010 Completed.HVA MVA.HVA, Viral AV 011 Completed MVA.HVA AV 016 Completed MVA.HVA.HVA MVA.HVA,, Viral AV A001 Completed tgaac09 A denoassociated Virus AV A002 Completed tgaac09 A denoassociated Virus Kenya, United Kingdom Switzerland, United Kingdom United Kingdom Belgium, Germany, ndia Uganda, Zambia AV A003 Ongoing AAV1-PG9 Vectored mmu United Kingdom noprophylaxis AV B001 Completed Ad35-GRN/EN Ad35-GRN/EN V V AV B002 Completed Adjuvanted GSK investigational HV vaccine formulation 1 Adjuvanted GSK investigational HV vaccine formulation 2 Ad35-GRN Vector -,, AV B003 Completed Ad26.EnvA-01 Ad35-ENV Vector - AV B004 Completed HV-MAG Ad35-GRN/EN V, Viral Vector - AV C001 Completed ADVAX AV C002 Completed ADMVA Kenya, Uganda, Zambia Kenya, Rwanda, South Africa, Kenya, Rwanda, Uganda
15 AV C003 Completed ADMVA AV Completed ADVAX C004/DHO-614 AV D001 Completed TBC-M4 ndia / AV N004 HV- CORE 004 Completed Ad35-GRN MVA.HVconsv psg2.hvconsv psg2.hvconsv,, AV P001 Completed ADVAX TBC-M4, Viral AV P002 Completed ADVAX TBC-M4, Viral AV R001 Completed rcad26.mos1. HVEnv Replicating AV S001 Completed SeV-G Ad35-GRN Replicating, AV T001 Ongoing PGT121 Passive AV V001 Completed VRC-HV0 VRC-HVADV0, Viral VP VP Vector - AV V002 Withdrawn VRC-HV0 VRC-HVADV0, Viral VP VP Vector - DEA EV06 Completed -HV- PT123 HV01 Ongoing Full-Length Single Chain (FLSC) Kenya ndia United Kingdom Kenya, United Kingdom, Rwanda Kenya, Rwanda Kenya, Rwanda, Uganda, Zambia ADSVAX B/E, Uganda
16 MPAACT P1112 Ongoing VRC-HVMAB AB Passive PCAVD006 Completed MVA mosaic PCAVD008 Completed Trimeric gp140 / PCAVD009 Ongoing Ad26.Mos.HV Trivalent gp140 C MVA mosaic,,, Puerto Rico, South Africa, Rwanda, Thailand, Uganda PCAVD010 Ongoing Ad26.Mos.HV gp140 C Trivalent, SS P-001 Completed Tat vaccine taly SS P-002 Completed Tat vaccine HV-1 delta-v2 Env vaccine, taly LFn-p24 Completed LFn-p24 vaccine MCA-0835 Completed 3BNC117 Passive Germany, Merck Completed Ad-5 HV-1 gag MRKAd5 HV-1 V (Merck) gag Vector - MRC V001 Completed rgp120w61d United Kingdom MRK Ad5 Completed Ad-5 HV-1 gag (Merck) MRKAd5 + Completed MRKAd5 HV-1 ALVAC-HV ALVAC gag Mucovac2 Completed CN54gp140 United Kingdom MV1-F4 Completed Measles Vector Belgium - GSK Replicating MYM-V101 Completed Virosome-Gp41 Belgium / NCHECR-AE1 Completed phs-hv-ae rfpv-hv-ae, Viral Thailand
17 up Ongoing Ad4-mgag Ad4-EnvC150 Replicating, Replicating PXVX- HV PACTG 230 Completed ADSVAX B/E rgp120/hv-1, b PAVE100 Withdrawn VRC-HV0 VRC-HVADV0, Viral VP VP Vector - PEACH-04 Ongoing ChAdV63.HVc MVA.HVconsv United Kingdom onsv PedVacc001 & PedVacc002 Completed MVA.HVA Gambia, Kenya PolyEnv1 Closed to follow-polyenv1 RSVAC02 Completed MVA-B RisVac02 boost Scheduled MVA-B RV 124 Completed ALVAC-HV gp160mn/la-2 / RV 132 Completed ALVAC-HV vcp1521 gp160 rgp120/hv-1 THO23/LA-DD, Spain Spain Thailand / RV 135 Completed ALVAC-HV gp120 C4-V3 Thailand vcp1521 RV 138; B011 Completed ALVAC-HV RV 144 Completed ALVAC-HV ADSVAX Thailand vcp1521 gp120 B/E RV 151 / WRAR 984 Completed LFn-p24
18 RV 156 Completed VRC-HV VP RV 156A Completed VRC-HV0 VRC-HVADV0, Viral VP VP Vector - RV 158 Completed MVA-CMDR / RV 172 Completed VRC-HV0 VRC-HVADV0, Viral VP VP Vector - Uganda Uganda Thailand, Kenya, Tanzania, Uganda RV 305 Ongoing ALVAC-HV ADSVAX B/E Thailand vcp1521 RV 306 Ongoing ALVAC-HV ADSVAX B/E Thailand vcp1521 RV 328 Ongoing ADSVAX B/E Thailand RV 365 Completed MVA-CMDR RV262 Completed Pennvax-G MVA-CMDR, Viral Kenya, Tanzania, Uganda, SG06RS02 Terminated HV gp140 United Kingdom ZM96 TAB9 Completed TAB9 Cuba TaMoVac Completed HVS- MVA-CMDR, Viral Tanzania, Mozambique TAMOVAC-01- MZ Completed HVS- MVA-CMDR, Viral Mozambique Tiantan vacciniacompleted Chinese Tiantan vaccinia, Viral China HV Vaccine Vector - Tiantan vaccinia HV Vaccine and Replicating Completed Chinese Tiantan vaccinia, Viral Vector - Replicating TMB-108 Completed balizumab Passive China
19 / UB HV-1 MN China UB HV-1MN octameric - Australia study Completed Completed UB HV-1 Peptide mmunogen, Multivalent UB HV-1 Peptide mmunogen, Multivalent / UB V106 Completed UB HV-1 Peptide Vaccine, Microparticulate Monovalent UCLA MG-001 Completed TBC-3B UCLA MG-003 Completed ALVAC-HV UKHVCSpoke0 03 Completed - CN54ENV and ZM96GPN MVA-C CN54gp140, Viral, China Australia United Kingdom V24P1 Completed HV p24/mf59 Vaccine V3-MAPS Completed V3-MAPS Brazil, China, Australia, Thailand, V Completed MRKAd5 HV-1 gag/pol/nef V Terminated MRKAd5 HV-1 gag/pol/nef MRKAd5 HV-1 gag/pol/nef MRKAd5 HV-1 gag/pol/nef Vector -, V Completed MRKAd5 HV-1 MRKAd6 MRKAd5+6
20 MRKAd5 and MRKAd6 HV-1 Trigene Vaccines gag/pol/nef HV-1 Vector -, / VAX 002 Completed ADSVAX B/B ADSVAX B/E, VAX 003 Completed ADSVAX B/E Thailand VAX 004 Completed ADSVAX B/B Canada, Netherlands, Puerto Rico, VRC 004 Completed VRC-HV0 ( ) VP VRC 006 Completed VRC-HVADV0 ( ) VP VRC 007 Completed VRC-HV0 ( ) VP VRC 008 Completed VRC-HV0 VRC-HVADV0, Viral ( ) VP VP Vector - VRC 009 Completed VRC-HV0 VRC-HVADV0, Viral ( ) VP VP Vector - VRC 010 Completed VRC-HVADV0 ( ) VP VRC Completed VRC-HV0 VRC-HVADV0, Viral 011( ) VP VP Vector - VRC 012 Completed VRC-HVADV0 VRC-HVADV0 ( ) VP VP Vector - VRC 015 ( ) Completed VRC-HVADV VP b VRC 016 Completed VRC-HV0 VRC-HVADV0, Viral VP VP Vector - VRC 602 Completed VRC-HVMAB0 Passive AB VRC 605 Ongoing VRC-HVMAB0 Passive
21 Powered by TCPDF ( AB VRC 607 Ongoing VRCHVMAB08 Passive 0-00-AB VRC01LS Ongoing VRCHVMAB08 Passive 0-00-AB / VR01 Completed MVA-B LPO-5 GTU-MultiHV France, X001 Completed CN54gp140 United Kingdom
A Quarterly Update on HIV Prevention Research. Vol. 8 No. 2
What is it? What could it do? Key Facts Antibodies Passive immunization is the transfer of pre-made antibodies to a person. Passive immunization using today's pre-made antibodies can involve infusion delivered
HVTN P5 Vaccine Trials
HVTN P5 Vaccine Trials Erica Andersen-Nissen, PhD Director, Cape Town HVTN Immunology Laboratory Considerations for a Pan-African HIV Vaccine Development Agenda Kigali, Rwanda 16-17 March 2015 HVTN Mission
Ongoing HVTN Trials (Enrolling, In Follow-up, and in Long Term Follow-up)
Ongoing HVTN Trials (, In, and in ) HVTN 085 90 HVTN VRC rad5 multiclade 02/2012 Boston - Brigham; Chicago; Nashville; New York - NYBC; New York - NYBC - Bronx; Philadelphia; Rochester; San Francisco;
HIV vaccine research and development
HIV vaccine research and development What is an HIV vaccine and how does it work? An HIV vaccine is a substance given to the body to teach it to defend itself against HIV. A successful preventative HIV
EDCTP Third Forum PARTNERSHIP AND AFRICAN LEADERSHIP IN VACCINE RESEARCH AND HIV/AIDS DRUG. MBOUP Souleymane
EDCTP Third Forum PARTNERSHIP AND AFRICAN LEADERSHIP IN VACCINE RESEARCH AND HIV/AIDS DRUG MBOUP Souleymane HIV VACCINE IN AFRICA In 2005, 13 new trials of preventive AIDS vaccine candidates began in 9
Impact of the Proposed Cuts to HIV/AIDS Research. Kevin Fisher AVAC September 7, 2017
Impact of the Proposed Cuts to HIV/AIDS Research Kevin Fisher AVAC September 7, 2017 President s FY18 Budget Cuts $544 m from the FY 2017 NIH HIV/AIDS research budget levels A cut of 18.5% FY 18 Cut FY
Ongoing HVTN Trials. Protocol N Trial Collaborators HVTN HVTN VRC DAIDS. Study Product(s)
HVTN 076 17 HVTN DNA multiclade rad5 multiclade 09/2011 The study looks at the immune response of genital and rectal tissues to injections of a DNA vaccine followed by a recombinant adenovirus serotype
Start Date* Sites Description
HVTN 076 17 HVTN HVTN 084 100 HVTN HVTN 085 90 HVTN HVTN 096 96 HVTN IPPOX EuroVacc GSID USMHRP HVTN 098 94 HVTN Inovio clade B AIDSVAX B/E clade C NYVAC clade C PENNVAX-GP IL-12 adjuvant September-11
The History of HIV Vaccine Development
The History of HIV Vaccine Development a short story on 30 years of research å Dr. Jill Gilmour International AIDS Vaccine Initiative Barcelona, 6 October 2013 IAVI is a product-development partnership
May HIV Vaccines: The Basics
May 2018 HIV Vaccines: The Basics Presentation Overview What is a vaccine? How would an HIV vaccine work? Where are we in the search? What is needed now? What is a Vaccine? A substance that teaches the
Trial Collaborators Start Date* Sites Stage HVTN BMGF IPPOX EuroVacc GSID. HVTN DAIDS GSK Sanofi Jun 2017
Ongoing s:, In, Health/AESI Contact(s) 096/EV04 106 107 108 110 A phase 1 double blind placebo-controlled clinical trial to evaluate the safety and to compare the priming ability of NYVAC alone versus
Trials & Tribulations: on the way to cure: where do HIV Vaccines fit in? Glenda Gray SA HIV Clinicians Society Conference April, 2016
Trials & Tribulations: on the way to cure: where do HIV Vaccines fit in? Glenda Gray SA HIV Clinicians Society Conference 2016 13-16 April, 2016 Scope Rationale for an HIV vaccine RV144 study in Thailand
New Preventive Technology: Providing New Options to Stop the Spread of HIV/AIDS. Dublin, Ireland. June 24, AIDS Vaccines.
New Preventive Technology: Providing New Options to Stop the Spread of HIV/AIDS Dublin, Ireland June 24, 2004 AIDS Vaccines - An R&D Briefing This paper has been prepared by the International AIDS Vaccine
HIV Vaccine Clinical Trials at CIDRZ
HIV Vaccine Clinical Trials at CIDRZ Developing a Safe and Effective Vaccine for Prevention of HIV Infections Globally Christine Namakobo Senior Research Nurse Matero Clinical Research Site State of Global
ADVOCACY IN UNCERTAIN TIMES. A call to action HIV VACCINE AWARENESS DAY MAY 18
ADVOCACY IN UNCERTAIN TIMES A call to action HIV VACCINE AWARENESS DAY 2017 MAY 18 2 HIV VACCINE AWARENESS DAY 2017 POLITICAL WILL A call to action These are hectic times. There is more information coming
Advancing HIV Vaccines into Efficacy studies. Glenda Gray WHO PD VAC 7-9 September 2015 Geneva, Switzerland
Advancing HIV Vaccines into Efficacy studies Glenda Gray WHO PD VAC 7-9 September 2015 Geneva, Switzerland What we need to end AIDS: controlling viremia New classes of Drugs Point of care viral load &
HIV and Challenges of Vaccine Development
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health HIV and Challenges of Vaccine Development Richard A. Koup, MD INTEREST
Professor Jonathan Weber
THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Professor Jonathan Weber Imperial College, London 1-4 April 2014, Arena and Convention Centre Liverpool THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Professor
Current State of Global HIV Care Continua. Reuben Granich 1, Somya Gupta 1, Irene Hall 2, John Aberle-Grasse 2, Shannon Hader 2, Jonathan Mermin 2
Current State of Global HIV Care Continua Reuben Granich 1, Somya Gupta 1, Irene Hall 2, John Aberle-Grasse 2, Shannon Hader 2, Jonathan Mermin 2 1) International Association of Providers of AIDS Care
Current State of HIV Vaccine Development
Current State of HIV Vaccine Development Sandhya Vasan, MD US Military HIV Research Program Henry M. Jackson Foundation Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand AVAC HVAD
Progress in HIV Vaccine Development Magdalena Sobieszczyk, MD, MPH. Division of Infectious Diseases Columbia University Medical Center
Progress in HIV Vaccine Development Magdalena Sobieszczyk, MD, MPH Division of Infectious Diseases Columbia University Medical Center 1 Outline A short history of HIV vaccine design and development Describe
4/14/2016. HIV Vaccines and Immunoprotection: Where Are We? Learning Objectives. After attending this presentation, participants will be able to:
HIV Vaccines and Immunoprotection: Where Are We? Mark J. Mulligan, MD, FIDSA Distinguished Professor of Medicine Emory University School of Medicine Atlanta, Georgia FINAL: 04/01/16 Atlanta, Georgia: Friday,
Vectored Vaccines for HIV: Status and Path Forward. Rick King International AIDS Vaccine Initiative
Vectored Vaccines for HIV: Status and Path Forward Rick King International AIDS Vaccine Initiative Thailand 2011 Acknowledgements IAVI R&D Chris Parks Wayne Koff Mike Caulfield ld Adrian McDermott Thomas
HIV Vaccine. Sunee Sirivichayakul, Ph.D. Faculty of Medicine Chulalongkorn University. August 22, 2014
HIV Vaccine Sunee Sirivichayakul, Ph.D. Faculty of Medicine Chulalongkorn University August 22, 2014 Immunity Natural immunity Active natural immunity e.g., infection Passive natural immunity e.g., trans-placental
The Kitchen Sink. Glenda Gray AIDS vaccine at the cross roads: how to adapt to a new preven9on age? Monday 7 th October, 2013, Barcelona
The Kitchen Sink Glenda Gray AIDS vaccine at the cross roads: how to adapt to a new preven9on age? Monday 7 th October, 2013, Barcelona The only important slide of my presentation. All efficacy trial in
Richard Jefferys Basic Science, Vaccines & Cure Project Director Treatment Action Group NASTAD Prevention and Care Technical Assistance Meeting
Richard Jefferys Basic Science, Vaccines & Cure Project Director Treatment Action Group NASTAD Prevention and Care Technical Assistance Meeting Washington, DC July 19, 2017 Pre-exposure prophylaxis (PrEP)
The Potential For Harnessing the Immune System to Control HIV
The Potential For Harnessing the Immune System to Control HIV Gordon Dickinson, MD Chief, Infectious Diseases, U Miami School of Medicine, and Co-Director, Special Immunology, Miami VA Medical Center The
TasP - Individual versus Public Health Benefit versus Both.
Site Map l Contact Us l Calendar l Join AVAC Donate TasP - Individual versus Public Health Benefit versus Both. Kevin Fisher Policy Director, AVAC June 2012 Multiple choice answer: all of the above We
T W O D E C A D E S, O N E M E S S A G E : P R E V E N T I O N M AT T E R S
8 7 6 5 4 3 2 1 V 7 YEARS AND COUNTING... VI IV III II AVAC? 4 to an AIDS Vaccine? 3 2 AIDS VACCINE ADVOCACY COALITION MAY 2001 AIDS VACCINE ADVOCACY COALITION MAY 2000 1 HOW DO YOU FIGHT A DISEASE OF
Planned Vaccine Trials to Follow-up on RV 144. Merlin Robb, MD Deputy Director for Clinical Research MHRP
Planned Vaccine Trials to Follow-up on RV 144 Merlin Robb, MD Deputy Director for Clinical Research MHRP Planned studies are mutually reinforcing and will amplify public health impact and regional relevance
Biomedical Prevention Update Thomas C. Quinn, M.D.
Biomedical Prevention Update Thomas C. Quinn, M.D. Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health Global
Drug resistance TB in People Living with HIV: research questions and priorities.
Drug resistance TB in People Living with HIV: research questions and priorities. Haileyesus Getahun, MD, PhD. Stop TB Department World Health Organisation Geneva, Switzerland Outline of presentation Definition
HIV Vaccines: New Frontiers in Vaccine Development
INVITED ARTICLE Kenneth H. Mayer, Section Editor HIV/AIDS HIV Vaccines: New Frontiers in Vaccine Development Ann Duerr, 1 Judith N. Wasserheit, 1,2 and Lawrence Corey 1,2 1 Clinical Research Division,
Start Date* Sites Description
076 17 083 180 084 100 085 90 098 94 Inovio rad35 clade A clade A rad clade B clade B PENNVAX-GP IL-12 adjuvant September-11 Seattle The study looks at the immune response of genital and rectal tissues
3.1 PHASE 2 OF THE GLOBAL PROJECT
RESULTS CHAPTER 3 3.1 PHASE 2 OF THE GLOBAL PROJECT (1996 1999) This new report of the Global Project provides data on anti-tuberculosis drug resistance from 58 geographical settings. Of these, 28 provided
WITH AN ESTIMATED7500 INcident
ORIGINAL CONTRIBUTION Vaccine-Induced HIV Seropositivity/Reactivity in ninfected HIV Vaccine Recipients Cristine J. Cooper, PhD Barbara Metch, MS Joan Dragavon, MLM Robert W. Coombs, MD, PhD Lindsey R.
Current VISP/R Practices Overview
Vaccine-Induced Sero-Positivity/ Sero-Reactivity(VISP/SR) Current VISP/R Practices Overview Mary A. Allen, R.N. M.S. National Institute of Allergy and Infectious Diseases National Institutes of Health,
HVTN Laboratory Program: Immunogenicity and Research Assays
HVTN Laboratory Program: Immunogenicity and Research Assays Erica Andersen-Nissen, PhD Director, Cape Town HVTN Immunology Laboratory Considerations for a Pan-African HIV Vaccine Development Agenda Kigali,
Country-wise and Item-wise Exports of Animal By Products Value Rs. Lakh Quantity in '000 Unit: Kgs Source: MoC Export Import Data Bank
Country-wise and Item-wise Exports of Animal By Products Value Rs. Lakh Quantity in '000 Unit: Kgs Source: MoC Export Import Data Bank Country CAPEXIL Description HS Code Value 2010-2011 Quantity 2010-2011
HPV Vaccines: Background and Current Status
HPV Vaccines: Background and Current Status Bogota, Colombia, 2007 Jon Kim Andrus, MD HPV and Cervical Cancer Evidence that HPV is essential: Documented molecular studies of cervical cancer Case-control
Vaccine Trial Centre. Established in1984 Funded by WHO on Control of Diarrhea Diseases Full operation in1986
Vaccine Trial Centre Established in1984 Funded by WHO on Control of Diarrhea Diseases Full operation in1986 Past 29 Years of Research Experiences Cholera Vaccine Killed whole cell and B sub-unit oral vaccine
Procedure for Expedited Review of imported pre-qualified vaccines for use in national immunization programmes
Procedure for Expedited Review of imported pre-qualified vaccines for use in national immunization programmes Dr Nora Dellepiane/Dr Anil Kumar Chawla WHO/HQ-Geneva, Switzerland 1 Expedited review procedure
THE CARE WE PROMISE FACTS AND FIGURES 2017
THE CARE WE PROMISE FACTS AND FIGURES 2017 2 SOS CHILDREN S VILLAGES INTERNATIONAL WHERE WE WORK Facts and Figures 2017 205 58 79 families and transit 31 Foster homes 162 8 3 173 214 2 115 159 136 148
SGCEP SCIE 1121 Environmental Science Spring 2012 Section Steve Thompson:
SGCEP SCIE 1121 Environmental Science Spring 2012 Section 20531 Steve Thompson: steventhompson@sgc.edu http://www.bioinfo4u.net/ 1 First, a brief diversion... Into... how to do better on the next exam,
Lessons learned from the IeDEA West Africa Collaboration
Lessons learned from the IeDEA West Africa Collaboration François DABIS with the contribution of Didier Koumavi EKOUEVI INSERM U-897, Bordeaux, France, Programme PACCI, ANRS site, Abidjan, Côte d Ivoire
HIV Vaccine. 15 September 2016 นพ.นคร เปรมศร ผ อ านวยการส าน กงาน โครงการศ กษาว คซ นเอดส ทดลอง
HIV Vaccine 15 September 2016 นพ.นคร เปรมศร ผ อ านวยการส าน กงาน โครงการศ กษาว คซ นเอดส ทดลอง GLOBAL STATISTICS 2015 17 million people were accessing antiretroviral therapy 36.7 million people globally
Tobacco: World Markets and Trade
United States Department of Agriculture Foreign Agricultural Service Circular Series FT -09-05 Sep. 2005 List of Tables Tobacco: World Markets and Trade Table 2 U.S. Tobacco Trade: 2004-2005 Table 3 Unmanufactured
GOVX-B11: A Clade B HIV Vaccine for the Developed World
GeoVax Labs, Inc. 19 Lake Park Drive Suite 3 Atlanta, GA 3 (678) 384-72 GOVX-B11: A Clade B HIV Vaccine for the Developed World Executive summary: GOVX-B11 is a Clade B HIV vaccine targeted for use in
HIV treatment trials using novel strategies and drug combinations
SECOND JOINT CONFERENCE OF BHIVA AND BASHH 2010 Dr Sheena McCormack MRC Clinical Trials Unit, London 20-23 April 2010, Manchester Central Convention Complex HIV treatment trials using novel strategies
SCIENTIFIC BLUEPRINT 2000: ACCELERATING GLOBAL EFFORTS AIDS VACCINE DEVELOPMENT JULY
S C I E N T I F I C B L U E P R I N T 2 0 0 0 SCIENTIFIC BLUEPRINT 2000: ACCELERATING GLOBAL EFFORTS IN AIDS VACCINE DEVELOPMENT JULY 2000 S C I E N T I F I C B L U E P R I N T 2 0 0 0 SCIENTIFIC BLUEPRINT
Novel HIV Prevention Methods for Women
Novel HIV Prevention Methods for Women State of the art injectables, rings, and antibody-mediated prevention Nyaradzo M Mgodi (MBChB, MMed) Principal Investigator University of Zimbabwe- College of Health
World Connections Committee (WCC) Report
World Connections Committee (WCC) Report 06 Co-Dependents Anonymous Service Conference Countries Where CoDA Exists This report reflects the World Connections Committee (WCC) support of the growth and development
The first and only fully-automated, multiplexed solution for Measles, Mumps, Rubella and Varicella-zoster virus antibody testing
Bio-Rad Laboratories BioPlex 2200 System BioPlex 2200 MMRV IgG Kit The first and only fully-automated, multiplexed solution for Measles, Mumps, Rubella and Varicella-zoster virus antibody testing Bio-Rad
HIV-1 Vaccine Trials: Evolving Concepts and Designs
Send Orders of Reprints at bspsaif@emirates.net.ae 274 The Open AIDS Journal, 2012, 6, 274-288 HIV-1 Vaccine Trials: Evolving Concepts and Designs Open Access Missa P. Sanou 1, Anne S. De Groot 2, Michael
Inspiring HIV Prevention Innovations for Women. IPM Satellite Event Durban, 13 th June 2017 Annalene Nel
Inspiring HIV Prevention Innovations for Women IPM Satellite Event Durban, 13 th June 2017 Annalene Nel HIV Infection: Where We Are Today 30+ years since the US CDC reported the first cases of AIDS 25.5
CND UNGASS FOLLOW UP
CND UNGASS FOLLOW UP INCB follow-up activities on Chapter 2. Operational recommendations on ensuring the availability of and access to controlled substances exclusively for medical and scientific purposes,
Pandemic H1N Dr. Maria Neira Global Influenza Programme WHO, Geneva
Pandemic H1N1 2010 Dr. Maria Neira Global Influenza Programme WHO, Geneva WHO Role during pandemic (H1N1) 2009 Under the International Health Regulations (2005) Detect event (notification by Member States
- Network for Excellence in Health Innovation
Real-world evidence is evidence from any and all sources of data that may contribute to more effective health care, including health care best tailored to the needs of individual patients. - Network for
Recommended composition of influenza virus vaccines for use in the 2007 influenza season
Recommended composition of influenza virus vaccines for use in the 2007 influenza season September 2006 This recommendation relates to the composition of vaccines for the forthcoming winter in the southern
10. RESEARCH AND DEVELOPMENT
page 170 Monitoring results: goals, strategic objectives and indicators 10. RESEARCH AND DEVELOPMENT Progress towards development of tb vaccines (Indicator SO6.1) Background In March 1993, WHO designated
JOINT TB AND HIV PROGRAMMING
JOINT TB AND HIV PROGRAMMING Haileyesus Getahun, WHO. On behalf of the Global Fund Interagency TB and HIV Working Group (Global Fund, PEPFAR, Stop TB Partnership, UNAIDS, WHO) I was admitted in a hospital
DNA Immunization for HIV Vaccine Development
University of Massachusetts Medical School escholarship@umms GSBS Student Publications Graduate School of Biomedical Sciences 2-25-2014 DNA Immunization for HIV Vaccine Development Yuxin Chen University
Regulatory Capacity Building and Developing Countries: CBER Perspective
Regulatory Capacity Building and Developing Countries: CBER Perspective Karen Midthun, M.D. Director Center for Biologics Evaluation and Research US Food and Drug Administration IOM Meeting Strengthening
Sponsor. Generic Drug Name. Trial Indication(s) Protocol Number. Protocol Title. Clinical Trial Phase. Study Start/End Dates. Novartis.
Sponsor Novartis Generic Drug Name Lumiracoxib Trial Indication(s) Not applicable Protocol Number CCOX189A2483 Protocol Title A retrospective pharmacogenetics analysis of patients with elevated liver enzymes
Annex 2 A. Regional profile: West Africa
Annex 2 A. Regional profile: West Africa 355 million people at risk for malaria in 215 297 million at high risk A. Parasite prevalence, 215 Funding for malaria increased from US$ 233 million to US$ 262
Evaluation of lead HIV-1 vaccine regimen in APPROACH:
Evaluation of lead HIV-1 vaccine regimen in : Phase 1/2a study testing heterologous prime boost regimens using mosaic Ad26 and MVA vectors combined with Env protein Hanneke Schuitemaker Martin Freeman,
Case study of formulating two Subtype C gp120 proteins
Case study of formulating two Subtype C gp120 proteins Antu Dey, DPhil. Senior Director, IAVI (formerly at GSK Vaccines) Associate Project Leader HIV Research Head Formulation Sciences & Process Development
Global EHS Resource Center
Global EHS Resource Center Understand environmental and workplace safety requirements that affect your global operations. 800.372.1033 bna.com/gelw Global EHS Resource Center This comprehensive research
Main global and regional trends
I N T R O D U C T I O N Main global and regional trends Promising developments have been seen in recent years in global efforts to address the AS epidemic, including increased access to effective treatment
ACCELERATING THE GLOBAL EFFORT FOR HIV VACCINE RESEARCH
WHO/IVB/06.07 ÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆÆ ACCELERATING THE GLOBAL EFFORT FOR HIV VACCINE RESEARCH Af r i c a Af r i c a A LITTLE C ACCELERATING THE GLOBAL EFFORT FOR HIV VACCINE
Progress on new vaccine strategies against chronic viral infections
Progress on new vaccine strategies against chronic viral infections Jay A. Berzofsky,, Masaki Terabe, Igor M. Belyakov J Clin Invest. 2004;114(4):450-462. https://doi.org/10.1172/jci22674. Review Among
HIV Vaccine: Recent Advances, Current Roadblocks, and Future Directions
Florida International University FIU Digital Commons Department of Health Promotion and Disease Prevention Robert Stempel College of Public Health & Social Work 10-5-2015 HIV Vaccine: Recent Advances,
A global approach to HIV-1 vaccine development
A global approach to HIV-1 vaccine development The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. Citation Published Version Accessed
Are we targeting the right HIV determinants?
QuickTime et un décompresseur TIFF (non compressé) sont requis pour visionner cette image. AIDS Vaccine 2009 October 22 nd 2009 - Paris Are we targeting the right HIV determinants? Françoise BARRÉ-SINOUSSI
FUNDERS UPDATE- BMGF. Third HIV Env Manufacturing Workshop Sponsored by DAIDS-NIAID-NIH and the HIV Global Vaccine Enterprise July 20-21, 2017
FUNDERS UPDATE- BMGF Third HIV Env Manufacturing Workshop Sponsored by DAIDS-NIAID-NIH and the HIV Global Vaccine Enterprise July 20-21, 2017 Susan Barnett Senior Program Officer, Product and Clinical
World Health Organization Organisation mondiale de la Santé
World Health Organization Organisation mondiale de la Santé DISTRIBUTION RESTRICTED EXECUTIVE BOARD Ninety-seventh Session Provisional agenda item 17.1 EB97/NGO/11 18 October 1995 Application from an international
Development of prophylactic vaccines against HIV-1
Schiffner et al. Retrovirology 2013, 10:72 REVIEW Open Access Development of prophylactic vaccines against HIV-1 Torben Schiffner 1, Quentin J Sattentau 1* and Lucy Dorrell 2,3 Abstract The focus of most
Comments made today contain forward looking statements as described under the Private Securities Litigation Reform Act of Our forward looking
EBOLA HIV January 2015 Comments made today contain forward looking statements as described under the Private Securities Litigation Reform Act of 1995. Our forward looking statements represent our current
Faculty/Presenter Disclosure. HIV Update Outline. Undetectable = Untransmissable HTPN 052. Partner Opposites attract 9/28/2018
Faculty/Presenter Disclosure HIV Update 2018 Dr. Joss de Wet Clinical Assistant Professor Family Medicine UBC Faculty: Joss de Wet Relationships with financial sponsors: Speakers Bureau/Honoraria: Gilead,
Correlates of Immunity: RV144 - Lessons Learned
Correlates of Immunity: RV144 - Lessons Learned US Military HIV Research Program (MHRP) Nelson L. Michael, MD, PhD AIDS Vaccine 2010, Atlanta GA 01 October 2010 Outline RV 144 Correlates Discovery Towards
WELLNESS COACHING. Wellness & Personal Fitness Solution Providers
WELLNESS COACHING Wellness & Personal Fitness Solution Providers Introducing Ourselves... We are Personal Wellness Coaches 2 We help people look and feel better by: - Educating on proper nutrition (80%)
ISBT WP-TTID Annual Report for Subgroup on Virology Drs. Michael Busch, Kurt Roth and Susan Stramer
ISBT WP-TTID Annual Report for Subgroup on Virology Drs. Michael Busch, Kurt Roth and Susan Stramer Questionnaire on NAT Screening of Blood Donations for an International Forum on 10 years of NAT Screening
Undetectable = Untransmittable. Mariah Wilberg Communications Specialist
Undetectable = Untransmittable Mariah Wilberg Communications Specialist Undetectable=Untransmittable PLWH who get and stay undetectable have effectively no risk of transmitting HIV to their sex partners
AIDS by the Numbers: Where Do We Stand with ? Peter Ghys, UNAIDS
AIDS by the Numbers: Where Do We Stand with 90-90-90? Peter Ghys, UNAIDS ACHIEVING THE 90 90 90 TARGETS, 2016 FIGURE 3.2. COUNTRIES THAT HAVE ACHIEVED THE 90 90 90 TARGETS OR ARE NEAR TO ACHIEVING THEM,
Update on Biomedical Prevention. Thomas C. Quinn, MD, MSc
Update on Biomedical Prevention Thomas C. Quinn, MD, MSc Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health
HIV DIAGNOSTIC TESTS IN LOW- AND MIDDLE-INCOME COUNTRIES: FORECASTS OF GLOBAL DEMAND FOR
HIV DIAGNOSTIC TESTS IN LOW- AND MIDDLE-INCOME COUNTRIES: FORECASTS OF GLOBAL DEMAND FOR 2015 2020 Presented by Vincent Habiyambere (WHO), Biyi Adesina (Avenir Health) and Meghan Wareham (CHAI) on behalf
Vaccines against Rotavirus & Norovirus. Umesh D. Parashar CDC, Atlanta, GA
TM Vaccines against Rotavirus & Norovirus Umesh D. Parashar CDC, Atlanta, GA 1 Rotavirus is the Leading Cause Of Severe Diarrhea in Children
Dr. Natella Rakhmanina Senior Technical Advisor, Elizabeth Glaser Pediatric AIDS Foundation October 2018
Dr. Natella Rakhmanina Senior Technical Advisor, Elizabeth Glaser Pediatric AIDS Foundation October 2018 1 Number of young people living with HIV (aged 15 19 years) by mode of HIV acquisition, 25 countries,*
Higher priming doses enhance HIV-specific humoral but not cellular. responses in a randomized, double-blind phase Ib clinical trial of
Higher priming doses enhance HIV-specific humoral but not cellular responses in a randomized, double-blind phase Ib clinical trial of preventive HIV-1 vaccines Pierre-Alexandre Bart a,b, Yunda Huang c,
ROTAVIRUS VACCINES. Virology
ROTAVIRUS VACCINES Virology Rotavirus is a triple-layers viral particle belonging to the Reoviridae family. It contains 11 segments of double-stranded RNA, of which 6 are structural and 5 are non-structural
PRACTICE POINTS AIDS Vaccine 2001: Looking to the Future
PRACTICE POINTS AIDS Vaccine 2001: Looking to the Future 1 Ronald T. Mitsuyasu 1 Associate Professor of Medicine, University of California Los Angeles, and Director of the UCLA CARE Center, UCLA Medical
Role of the Microbiome in HIV Vaccine Response Heterogeneity Ongoing and Future Microbiome Studies in HVTN Protocols
Role of the Microbiome in HIV Vaccine Response Heterogeneity Ongoing and Future Microbiome Studies in HVTN Protocols Microbiome in HIV Workshop Pathogenesis, Prevention and Treatment October 20 th, 2017
ICM: Trade-offs in the fight against HIV/AIDS
ICM: Trade-offs in the fight against HIV/AIDS 1 As the HIV/AIDS pandemic enters its 25 th year, both the number of infections and number of deaths due to the disease continue to rise. Despite an enormous
Main developments in past 24 hours
ECDC DAILY UPDATE Pandemic (H1N1) 2009 Update 02 October 2009, 09:00 hours CEST Main developments in past 24 hours Weekly Influenza Surveillance Overview to be published today; Media highlights and Eurosurveillance
Experiences on Workforce Development in Other Regions
Experiences on Workforce Development in Other Regions The USA Experience John MacArthur, MD, MPH (EIS 98) Director Thailand MOPH US CDC Collaboration CDC/Southeast Asia Regional Office Epidemic Intelligence
Rotavirus vaccines: Issues not fully addressed in efficacy trials
Rotavirus vaccines: Issues not fully addressed in efficacy trials TM Umesh D. Parashar Lead, Viral Gastroenteritis Team CDC, Atlanta, USA uparashar@cdc.gov 1 Two New Rotavirus Vaccines Licensed in 2006
BioPlex 2200 Infectious Disease Panels
BioPlex 2200 System BioPlex 2200 Infectious Disease Panels An Expanding Multiplexed Assay Menu Lyme HIV Ag-Ab MMV IgM Syphilis Total & RPR MMRV EBV HSV-1 & HSV-2 EBV IgM ToRC IgM ToRC Leading the way with
Recommended composition of influenza virus vaccines for use in the influenza season
Recommended composition of influenza virus vaccines for use in the 2006 2007 influenza season This recommendation relates to the composition of vaccines for the forthcoming influenza season in the northern
10 Years of Laboratory Capacity Building. September 6-11 th, 2015 Les Pensieres, Veyrier-du-Lac, France
10 Years of Laboratory Capacity Building 6 th Advanced Course on Diagnostics September 6-11 th, 2015 Les Pensieres, Veyrier-du-Lac, France John N. Nkengasong, Ph.D Associate Director for Laboratory & Chief,
Pandemic (H1N1) (August 28, h GMT; 12 h EST) Update on the qualitative indicators
Regional Update Pandemic (H1N1) 29 (August 28, 29-17 h GMT; 12 h EST) Update on the qualitative indicators For Epidemiological Week 33 (EW 33), from 16 August to 22 August, 22 countries reported updated